Six-year duration of adjuvant imatinib in high-risk GIST: more to come

Jean Yves Blay; C Schiffler; Sylvie Chabaud; D Perolc; Axel Le Cesne

doi:10.1016/j.annonc.2024.11.013

Related publications

Letter2024

Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come

Jean Yves Blay, C Schiffler, Sylvie Chabaud, D Perolc, Axel Le Cesne

Letter2024

Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse

Jean Yves Blay, Nicolas Penel, C Schiffler, Sylvie Chabaud, David Pérol, Axel Le Cesne

Article2024

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Jean Yves Blay, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Clémence Hénon, I. Ray-Coquard, K Armoun, Sébastien Salas, Mariella Spalato Ceruso, Antoine Adenis, B. Verret, Nicolas Penel, Camille Moreau-Bachelard,

Article2024

55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Axel Le Cesne, Sylvie Chabaud, O. Bouche, Nicolas Penel, Mehdi Brahmi, Maud Toulmonde, Emmanuelle Bompas, François Bertucci, L. Chaigneau, W. Lahlou, B. Landi, B. Verret, Clémence Hénon, Diane Pannier, Marc Pracht, Olivier Collard, Isabelle Laure Ray-Coquard, Séverine Metzger, David Pérol, Jean Yves Blay

Article2024

VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Axel Le Cesne, Camille Schiffler, Olivier Bouché, Mehdi Brahmi, F. Duffaud, Maud Toulmonde, B. Landi, W. Lahlou, Diane Pannier, Emmanuelle Bompas, François Bertucci, L. Chaigneau, Olivier Collard, Marc Pracht, Antoine Adenis, Isabelle Ray‐Coquard, Séverine Metzger, Sylvie Chabaud, David Pérol, Jean Yves Blay

Six-year duration of adjuvant imatinib in high-risk GIST: more to come

Discussion(0)

Related publications

Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come

Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse